Valneva Shares Drop 5.95% Amid Downward Revision

Session Closing Details

The stock ended the session down 5.95% at €4.524, compared to €4.81 the previous day. This downward movement is part of a challenging sequence after reaching a peak of €5.42 in early October, with the value losing 9.45% over the last seven days. Trading volumes remained moderate, accounting for 0.59% of the capital, in a generally downward Parisian market, with the CAC 40 dropping 1.53%. Despite this recent correction, the stock maintains an annual performance of 74.67%, significantly outperforming the reference index, which has advanced 4.73% over the same period.

Financial Forecast and Funding

This downward trend follows the announcement on October 6 of a downward revision of the 2025 financial forecasts by the vaccine specialist company. Valneva now expects annual revenues of between €165 and €180 million, down from the previous target of between €180 and €190 million. This revision comes in the context of the suspension at the end of August of the commercialization license for its chikungunya vaccine Ixchiq in the United States by the American health agency. Concurrently, the laboratory announced it had secured new financing of up to $500 million from Pharmakon Advisors, allowing it to postpone the repayment deadline to the fourth quarter of 2030 and improve its financial conditions.

Technical Perspective

Technically, the stock is trading above its 50-day moving average, established at €4.19, a position that reflects a structural rebound despite the week's fluctuations. This setup suggests that investor interest has been maintained beyond the levels observed during the summer. The relative strength index, at 62, is in a neutral-positive zone, indicating still favorable momentum without signaling overheating. Volatility remains high, measured at 18.27% over a month, reflecting the amplitude of recent movements in a context of multiple announcements.